How This Fidelity Fund Earned Healthy Returns in an Ailing Market

The Fidelity Select Medical Technology and Devices Portfolio bested its peers in 2018 with returns of 16 percent.

As 2018 came to an end, most investors were recoiling from the worst stock market in 10 years, with every benchmark bleeding losses and confusing even the most stalwart money managers. Except Eddie Yoon.

His Fidelity Select Medical Technology and Devices Portfolio has no peers among the 200 U.S.-based mutual funds greater than $5 billion. Fidelity Select Medical, based in Boston, enriched shareholders by more than 16 percent while the Dow Jones Industrial Average, S&P 500 and Nasdaq lost as much as 5 percent.

This is no one-year wonder. The 38-year-old Yoon has consistently outperformed the rest of the market the past decade. He attributes his go-getter instincts to immigrant parents from South Korea who encouraged him to follow them into medicine and become a doctor. Instead he detoured during his pre-med curriculum at Brown University to an internship in financial services and made health care his specialty at J.P. Morgan after he graduated. He joined Fidelity in 2006 and extols health care investing because it makes money in bull and bear cycles alike while saving lives.

Yoon explained his thinking in a telephone interview last month:

Almost every country is getting older. Inside the United States, over 10,000 people turn 65 every day. This is the Medicare population. And utilization really takes a step up when you turn 65, and then it takes another big step when you turn 75. The health care industry is structured in a way where innovation happens in the U.S. and it’s generally exported around the world. So within medical technology – for a lot of these companies – half the revenues are generated in the U.S. and half the revenues are generated outside the U.S.

That makes health care uniquely “recession resistant,” he said.

Since he began managing the fund in 2007, Fidelity Select Medical has crushed every equity benchmark. In the 10 years Yoon delivered 389 percent, the S&P 500, Russell 3000 and S&P Health Care Index gained 274 percent, 276 percent and 297 percent, respectively. During the past five years, Fidelity Select Medical appreciated 106 percent when the S&P 500, Russell 3000 and MSCI Health Care Index increased 81 percent, 47 percent and 64 percent. Yoon provided a similar bonanza the past three years when Fidelity Select Medical advanced 56 percent against 31 percent, 30 percent and 25 percent, according to data compiled by Bloomberg.

But the reason Fidelity Select Medical’s total return (income plus appreciation) was more than twice that of MSCI Health Care’s 361 companies last year is Yoon’s emphasis on less-risky equipment instead of biotechnology, where “you’re trying to solve problems of human biology.” That’s expensive, and full of thorny questions like “why some people get some cancers and people who have smoked for 15 years don’t get lung cancer.”

Yoon’s penchant “to buy low, sell high” by determining the future value of his favorite companies is the secret sauce of his success.
“You don’t want to own the best stories,” he says. “You want to own the best stocks.”

Yoon’s strategy is anticipating earnings and free cash flows in three to five years. “We’re trying to take advantage of where we see insights, and as market prices appreciate, some of those insights become more fully” valued “and when that happens we tend to seek out ideas in other parts of the market.”

While health care equipment makers and suppliers enabled Yoon to outperform his benchmarks, he reduced some of his holdings in the industry, including UnitedHealth, Baxter International Inc., Integra LifeSciences Holdings Corp., HCA Healthcare Inc. and DexCom Inc., according to data compiled by Bloomberg. At the same time he acquired more shares of Becton Dickinson, Abbott Laboratories, Thermo Fisher Scientific Inc., Medtronic Plc. and Intuitive Surgical Inc.

“The best way to create wealth for shareholders is to compound returns,” says Yoon. “It’s not just compounding at any level of risk; you want to do it at the lowest risk possible.”

Sure enough, Yoon’s ability to outperform the health care industry improved steadily over the past 10 years. During the 60 months between 2008 and 2012, Fidelity Select Medical was ahead of MSCI Healthcare in 30 of them, according to data compiled by Bloomberg. Between 2013 and 2017, the fund was the winner in 58 percent of those months and last year the ratio climbed to 75 percent, according to data compiled by Bloomberg.

“I don’t strive to be the No. 1 performing fund in any given year,” says Yoon. “But in the long run I want to deliver best-in-class investment performance.”

The would-be doctor gets another reward: “The great thing about this job is we get to see the cutting edge of science three to five years before it impacts patients.”
### TOTAL RETURNS AND EXPENSE RATIOS (%)

<table>
<thead>
<tr>
<th>Ticker</th>
<th>Fund</th>
<th>1-Year</th>
<th>3-Year</th>
<th>5-Year</th>
<th>10-Year</th>
<th>LOF^</th>
<th>Expense Ratios</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Gross</td>
</tr>
<tr>
<td>FSMEX</td>
<td>Fidelity Select Medical Technology and Devices Portfolio*</td>
<td>17.76</td>
<td>19.32</td>
<td>18.11</td>
<td>18.32</td>
<td>14.79</td>
<td>0.73</td>
</tr>
<tr>
<td>SLSAX</td>
<td>BlackRock Health Sciences Opportunities Portfolio Investor A Shares</td>
<td>12.35</td>
<td>13.19</td>
<td>12.61</td>
<td>16.67</td>
<td>14.96</td>
<td>1.15</td>
</tr>
<tr>
<td>MSQEX</td>
<td>Morgan Stanley Institutional Fund, Inc. Growth Portfolio Class I</td>
<td>15.45</td>
<td>26.56</td>
<td>17.65</td>
<td>19.96</td>
<td>11.68</td>
<td>0.59</td>
</tr>
<tr>
<td>FSHX</td>
<td>Fidelity Select Health Care Portfolio</td>
<td>7.31</td>
<td>13.24</td>
<td>10.52</td>
<td>18.58</td>
<td>15.64</td>
<td>0.71</td>
</tr>
<tr>
<td>ARIEX</td>
<td>Akre Focus Fund Institutional Class</td>
<td>23.17</td>
<td>22.51</td>
<td>15.55</td>
<td>–</td>
<td>17.17</td>
<td>1.05</td>
</tr>
<tr>
<td>FSBDX</td>
<td>Fidelity Series Blue Chip Growth Fund*</td>
<td>10.66</td>
<td>22.54</td>
<td>14.78</td>
<td>–</td>
<td>15.63</td>
<td>0.00</td>
</tr>
<tr>
<td>TRLGX</td>
<td>T. Rowe Price Institutional Large Cap Growth Fund</td>
<td>9.96</td>
<td>23.13</td>
<td>15.13</td>
<td>17.80</td>
<td>10.73</td>
<td>0.56</td>
</tr>
<tr>
<td>FSCHX</td>
<td>Fidelity Select Health Care Portfolio</td>
<td>15.45</td>
<td>25.99</td>
<td>18.60</td>
<td>21.17</td>
<td>16.16</td>
<td>0.72</td>
</tr>
<tr>
<td>PRNHX</td>
<td>T. Rowe Price New Horizons Fund</td>
<td>18.02</td>
<td>24.02</td>
<td>15.66</td>
<td>20.79</td>
<td>11.88</td>
<td>0.77</td>
</tr>
<tr>
<td>KAFUX</td>
<td>Federated Kaufmann Fund Class R</td>
<td>14.38</td>
<td>20.59</td>
<td>13.73</td>
<td>14.92</td>
<td>12.54</td>
<td>2.25</td>
</tr>
<tr>
<td></td>
<td>S&amp;P Health Care Select Sector Index</td>
<td>12.99</td>
<td>10.76</td>
<td>10.59</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>Russell 3000 Index</td>
<td>8.98</td>
<td>14.02</td>
<td>10.19</td>
<td>14.67</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>S&amp;P 500 Health Care Index</td>
<td>12.99</td>
<td>10.82</td>
<td>10.61</td>
<td>15.52</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>MSCI US IMI/Health Care 25-50 Index</td>
<td>11.51</td>
<td>11.90</td>
<td>11.02</td>
<td>16.09</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>Dow Jones Industrial Average</td>
<td>12.20</td>
<td>16.80</td>
<td>12.29</td>
<td>15.03</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>Nasdaq Composite Index</td>
<td>7.78</td>
<td>19.56</td>
<td>13.97</td>
<td>17.19</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>S&amp;P 500 Index</td>
<td>10.42</td>
<td>14.19</td>
<td>10.71</td>
<td>14.70</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

Note: Current performance may be higher or lower than that quoted. Visit institutional.fidelity.com or call your investment professional for most recent month-end performance of Fidelity funds. Performance data shown represents past performance and is no guarantee of future results. Investment return and principal value will fluctuate, so you may have a gain or loss when shares are sold.

It is not possible to invest directly in an index. All market indices are unmanaged. Index performance is not meant to represent that of any Fidelity mutual fund. Total returns are historical and include changes in share price and reinvestment of dividends and capital gains, if any.

* The fund is closed to new accounts with certain exceptions. Consult the prospectus for more details.

^ Life of fund (LOF) returns are from each fund’s inception date to indicated month-end. Fidelity Select Medical Technology and Devices Portfolio (4/28/98), BlackRock Health Sciences Opportunities Fund (12/22/99), Morgan Stanley Institutional Fund, Inc. Growth (4/21/99), Fidelity Select Health Care Portfolio (7/14/81), Akre Focus Fund (8/31/09), Fidelity Series Blue Chip Growth Fund (11/7/13), T. Rowe Price Institutional Large Cap Growth Fund (10/31/01), Fidelity Select Software & IT Services Portfolio (7/29/85), T. Rowe Price New Horizons Fund (6/3/60), Federated Kaufmann Fund (2/21/86).

### Fidelity Select Medical Technology and Devices Portfolio

#### TOP 10 HOLDINGS

- **BOSTON SCIENTIFIC CORP**
- **BECTON DICKINSON & CO**
- **THERMO FISHER SCIENTIFIC INC**
- **STRYKER CORP**
- **INTUITIVE SURGICAL INC**
- **DANAHER CORP**
- **ABBOTT LABORATORIES**
- **HOLOGIC INC**
- **MEDTRONIC PLC**
- **MASIMO CORP**

**% of Total Net Assets**

- **Top 10**: 60.21
- **Top 20**: 78.83
- **Top 50**: 98.24

**Total Holdings**: 61

The top 10 holdings may not be representative of the fund’s current or future investments and may change at any time. Top 10 holdings do not include money market instruments and/or futures contracts.
Information provided in this document is for informational and educational purposes only. To the extent any investment information in this material is deemed to be a recommendation, it is not meant to be impartial investment advice or advice in a fiduciary capacity and is not intended to be used as a primary basis for you or your client’s investment decisions. Fidelity and its representatives may have a conflict of interest in the products or services mentioned in this material because they have a financial interest in them, and receive compensation, directly or indirectly, in connection with the management, distribution, and/or servicing of these products or services, including Fidelity funds, certain third-party funds and products, and certain investment services.

Not NCUA or NCUSIF insured. May lose value. No credit union guarantee.

Stock markets, especially foreign markets, are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Foreign securities are subject to interest rate, currency exchange rate, economic, and political risks. The securities of smaller, less well-known companies can be more volatile than those of larger companies. The health care industries are subject to government regulation and reimbursement rates, as well as government approval of products and services, which could have a significant effect on price and availability, and can be significantly affected by rapid obsolescence and patent expirations.

Diversification does not ensure a profit or guarantee against a loss. It is important to remember that both active and passive strategies offer distinct advantages and disadvantages an investor should consider before investing. For example, while active management provides the potential for excess returns, this is in no way guaranteed, and active funds may significantly underperform their stated benchmark or the market as a whole. Investors should always consider the investment objectives, strategy, and risks of a particular investment in relation to their unique situation before investing. Please contact your investment professional to discuss what investment may be appropriate for you.

Gross Expense Ratio is the total annual fund or class operating expense ratio from the most recent prospectus (before waivers or reimbursements) and generally is based on amounts incurred during the most recent fiscal year. Management Fee is the fee paid by the fund to Fidelity Management & Research Company (FMR) for managing its investments and business affairs. Net Expense Ratio is the total annual fund or class operating expense ratio from the most recent prospectus, after any fee waiver and/or expense reimbursements that will reduce any fund operating expenses for no less than one year from the effective date of the fund’s registration statement. This number does not include any fee waiver arrangement or expense reimbursement that may be terminated without agreement of the fund’s board of trustees during the one-year period.

The stocks mentioned here are not necessarily holdings invested in by FMR LLC. References to specific companies should not be construed as a recommendation or investment advice. The statements and opinions are subject to change at any time, based on market and other conditions.

This reprint and any materials delivered with it should not be construed as an offer to sell or a solicitation of any offer to buy shares of any securities mentioned. Reprinted from the January 4, 2019, issue with permission from Bloomberg. The statements and opinions expressed in this article are those of the author. Fidelity Investments cannot guarantee the accuracy or completeness of any statements or data.

If receiving this piece through your relationship with Fidelity Institutional Asset Management®, (FIAM), this publication may be provided by Fidelity Investments Institutional Services Company, Inc., Fidelity Institutional Asset Management Trust Company, or FIAM LLC, depending on your relationship.

If receiving this piece through your relationship with Fidelity Personal & Workplace Investing (PWI) or Fidelity Family Office Services (FFOS), this publication is provided through Fidelity Brokerage Services LLC, Member NYSE, SIPC.

If receiving this piece through your relationship with Fidelity Clearing and Custody Solutions® or Fidelity Capital Markets, this publication is for institutional investor or investment professional use only. Clearing, custody, or other brokerage services are provided through National Financial Services LLC or Fidelity Brokerage Services LLC, Member NYSE, SIPC.

Before investing, consider the fund’s investment objectives, risks, charges, and expenses. Contact your investment professional or visit fidelity.com, institutional.fidelity.com, or 401k.com for a prospectus or, if available, a summary prospectus containing this information. Read it carefully.